Fundz

SpyGlass Pharma has raised $75 million in a Series D funding round led by Sands Capital to further its Drug Delivery Platform for glaucoma patients.

PUBLIC · SGPJun 02, 2025

Amount Raised

$75 Million

Round Type

Series D

Aliso ViejoBiotechnologyHealthcareHealth Care

Investors

Samsara BiocapitalVertex Ventures HCGilde HealthcareRA CapitalVensana CapitalNew Enterprise AssociatesSands Capital

Description

SpyGlass Pharma, an ophthalmic biotechnology company, confirmed a $75 million Series D financing round. This funding will aid in advancing their Drug Delivery Platform through two Phase III pivotal trials. The round was joined by Gilde Healthcare and existing investors. CEO Patrick Mooney expressed gratitude for investor support, highlighting the commitment to addressing unmet needs in ophthalmic patient care.

Who to call at SpyGlassPharma, and when

A new round usually means SpyGlassPharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day SpyGlassPharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at SpyGlassPharma, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

SpyGlassPharma

Location

27061 Aliso Creek Road

Aliso Viejo, California, United States

About

SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment SpyGlassPharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsRachel G., Vice President, Human Resources hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for SpyGlassPharma's next move

See what Strategic adds

SpyGlassPharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.